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Abstract

This manuscript investigates the negative sequelae (in particular, myalgia) of using
succinylcholine for patients undergoing tracheal intubation, pretreatment strategies to
minimize or eliminate these untoward effects, and compare their efficacy. Various
strategies are commonplace in the clinical setting, and there are a number of research
studies that discuss the efficacy of individual agents as well as compare them against
others. This manuscript explains the anatomy and physiology of neuromuscular
junctions, muscle contraction, and their relationship with muscle relaxants used in the
clinical setting.
Keywords: succinylcholine, fasciculations, myalgia, pretreatment, depolarizing
muscle relaxant, nondepolarizing muscle relaxant
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Comparing Pretreatment Modalities for the Prevention of Succinylcholine-Induced
Fasciculations in Adults Undergoing Endotracheal Intubation

Background/Statement of the Problem
Tracheal intubation is a medical procedure that involves inserting a flexible tube
into a patient’s trachea. This serves to secure the airway for surgical procedures and to
facilitate anesthesia drug administration. Tracheal intubation is accomplished by a multimodal approach that includes sedation, analgesia, and muscle relaxation, which produces
paralysis. Paralysis is necessary for this procedure due to the reflex mechanisms of the
laryngeal muscles, which surround the trachea (Nagelhout, 2014). Two types of muscle
relaxants are used for intubation: depolarizing and non-depolarizing. Succinylcholine is a
depolarizing muscle relaxant that is widely used in anesthesia for this purpose because it
has many qualities that are recognized as ideal, such as rapid onset, short duration of
action, a comfortable margin between muscular relaxation and respiratory
depression/arrest, and a controllable intensity. These qualities result in a patient who
needs less sedation and paralysis compared to longer-lasting sedatives and paralytic
agents. In many cases, intubation needs to occur very rapidly. The advantage of
succinylcholine, noted as far back as the 1950s, is its ability to meet these characteristics
(Foldes, McNall, & Borrego-Hinojosa, 1952). Succinylcholine’s ability to relax muscle
fibers in less than a minute, as well as fast recovery time in three to five minutes becomes
potentially life-saving in the event of a difficult or failed intubation (Abbas et al., 2009).
The mechanism of action of depolarizing muscle relaxants, such as
succinylcholine, is to mimic the neurotransmitter acetylcholine at the postsynaptic

2

nicotinic receptor. When two alpha subunits of this receptor are occupied, sodium passes
through the membrane and depolarizes the cell. When this happens, an action potential
occurs, which produces muscle contractions. Generating muscle contractions in order to
produce paralysis may seem counter-intuitive; however, succinylcholine produces a
sustained depolarization of this receptor, which prohibits it from repolarizing. The
inability to repolarize then prevents another depolarization of the cell by inactivating
sodium channels, which prevents further muscle contractions (i.e. paralysis). Sustained
muscular contractions are known as fasciculations, which may be viewed as visible, fast
contractions of muscle fibers. It is through this mechanism that succinylcholine produces
several adverse effects, including postoperative myalgia (which can last several days) and
increased serum potassium (Hochhalter, 1996). Therefore, minimizing these adverse
effects is a concern.
Some drugs, including non-depolarizing muscle relaxants, have been shown to
reduce fasciculations, and as a consequence, reduce adverse effects (True & Carter,
2003). Non-depolarizers antagonize the receptor, eliminating the incidence of action
potentials. This essentially decreases the number of receptors that succinylcholine can
influence, thus reducing fasciculations. A variety of other agents (not muscle relaxants)
work by different mechanisms, but still reveal a decreased incidence of fasciculations,
such as propofol, magnesium sulfate, lidocaine, and alfentanil (Hochhalter, 1996).
Therefore, the purpose of this project is to conduct a systematic review to
compare pretreatment modalities for the prevention of succinylcholine-induced
fasciculations in adults undergoing endotracheal intubation, as measured postoperative
myalgia. Next, a review of the literature will be presented.
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Literature Review
Databases used in this literature review were PubMed, Cinahl, Google Scholar,
and Web of Science. Keywords searched were “succinylcholine” and “fasciculations” in
the title or abstract. Additional keywords included “depolarizing muscle relaxant,”
“nondepolarizing muscle relaxant,” and “myalgia” and were used in combination with
succinylcholine and fasciculations in order to eliminate articles that did not use
succinylcholine. There were no restrictions on dates as to not exclude historical
literature.
Neuromuscular Junction Physiology and Receptor Theory
Skeletal muscle contraction is mediated by the peripheral nervous system. The
site where communication between the sensory and motor neurons occurs is called the
neuromuscular junction (NMJ). The NMJ is composed of three elements: the
presynaptic sensory nerve, the postsynaptic motor membrane, and the synaptic cleft
which lies between the two membranes. In order for communication to take place, an
action potential must take place. An action potential is the response of a cell to an
electrical impulse, which is mediated by the exchange of intracellular and extracellular
electrolytes, which is known as depolarization. This occurs when the electrical charge of
a cell rises above a certain threshold (Omar & Bollu, 2019). Immediately after
depolarization occurs, the cell will begin to repolarize which allows it to receive another
signal after a short refractory period. When depolarization occurs on the presynaptic
membrane, the neurotransmitter acetylcholine is released from the presynaptic structure
of the sensory neuron, crosses the synaptic cleft, and attaches to nicotinic receptors on the
postsynaptic structure. Each receptor has five subunits (the specific site of attachment):
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two alpha (α), and one each of beta (β), delta (δ), and epsilon (ε) subunits. Acetylcholine
only attaches to the alpha subunits. Furthermore, an action potential is possible only
when both alpha subunits are occupied by acetylcholine (Dani, 2015). When this
happens, the receptor undergoes a structural change, allowing sodium into that cell. This
produces an action potential in the cells of the motor neuron and eventually stimulates the
sarcoplasmic reticulum of the muscle to release calcium, which causes muscle
contraction (Kuo & Ehrlich, 2015).
In the synaptic cleft, the enzyme acetylcholinesterase is available in large
quantities to begin breaking down and recycling acetylcholine; this process begins almost
immediately. If this does not happen, muscular contraction would be sustained due to the
increased availability of acetylcholine. Therefore, acetylcholinesterase is the body’s
regulatory mechanism, which allows muscles to return to a resting state (Nagelhout,
2014).
Neuromuscular blocking agents
Muscle relaxants are medications administered that purposefully induce
relaxation. In anesthesia, the muscles are relaxed to the extent that paralysis occurs,
which is necessary for endotracheal intubation as well as many surgical procedures.
These medications block skeletal muscle action potentials by various mechanisms. Each
drug has a specific profile which includes its mechanism of action, speed of onset,
duration of action, and potential side effects. Neuromuscular blocking agents (NMBAs)
are divided into two classes: non-depolarizers and depolarizers (Gulenay & Mathai,
2018).
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Non-depolarizing agents. The mechanism of action of the non-depolarizing
agents is to competitively block the alpha subunits of the postsynaptic receptor. This
inhibits acetylcholine from occupying the site of action (Clar & Liu, 2019). This
inhibition essentially inactivates the receptor, which prohibits any further action
potentials. As a result, muscle contractions are prohibited for the life of that agent, which
are determined mostly by metabolism and redistribution. Metabolism depends on the
agent: some are metabolized in the liver, while others are metabolized by plasma
enzymes. Redistribution involves the movement of a drug in the body’s circulation,
which supplies various “compartments.” These compartments include those with high
blood flow and those with low blood flow. The heart, lungs, brain, kidneys, and liver are
considered high blood flow areas, while muscle, bone, and adipose tissue are examples of
low blood flow structures. A drug is essentially terminated when it is redistributed to
tissue compartments that have lower blood flow levels (such as adipose tissue) since
there are no receptors for the drug in that tissue (Nagelhout, 2014).
Depolarizing agents. The mechanism of action of depolarizing agents may at
first seem counterintuitive, since they produce depolarization and an action potential of
the postsynaptic motor neuron, producing muscle contraction. The only depolarizing
agent used in the United States (U.S.) is succinylcholine (Gulenay & Mathai, 2018). The
molecular structure of succinylcholine is identical to two molecules of acetylcholine.
Therefore, succinylcholine easily binds to both alpha subunits on the postsynaptic
receptor and produces an action potential, generating muscle contraction. However,
because succinylcholine is not susceptible to the same enzyme that breaks down
acetylcholine, it remains attached to the receptor. This attachment produces a sustained
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flow of sodium into the cell and therefore a series of muscle contractions, known as
fasciculations. By maintaining the electrical charge above the threshold, because of the
continued influx of sodium, it prohibits the cell from repolarizing. After a few moments,
this sustained depolarization eventually causes the receptors to become desensitized. The
muscle finally relaxes but because the receptors are still occupied by succinylcholine,
further depolarization is not possible until the succinylcholine disassociates and is
metabolized by different enzymes (Nagelhout, 2014).
Muscle Contraction Physiology
A cascade of events takes place when a signal is sent from the brain to a muscle
group by motor neurons, called a motor unit. On the presynaptic side of the NMJ, the
action potential opens calcium channels, and there is an influx of calcium, a positively
charged electrolyte, into the neuron. This increased positive charge causes vesicles that
contain acetylcholine to migrate to the outer membrane and begin the process that ends
with its rupture, which releases acetylcholine into the synaptic cleft. Some acetylcholine
crosses the cleft and attaches to the two alpha subunits of the nicotinic receptor while
others are almost immediately bound to acetylcholinesterase to begin the regulatory
process. On the postsynaptic side, another action potential is triggered when enough
acetylcholine attaches to their respective receptors, allowing an influx of sodium into that
cell. Thousands or millions of cells are clustered together in the matrix outside of the
sarcoplasmic reticulum (SR). Action potentials (electrical impulses) are essentially
generated simultaneously, which causes cells in the SR to release calcium. It is this
release of calcium that causes a unified contraction of muscle fibers (Kuo & Ehrlich,
2015).
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The importance of the contraction of skeletal muscles to animal life is obvious:
without skeletal muscle contractions, one could not walk, talk, eat, or breathe. Several
physiologic changes occur with the continued use of muscle groups. Anyone who has
been involved in physical exercise (from walking to weight training) knows some of
these intuitively: body temperature rises, and one may end up with sore muscles the
following day. These are normal and essentially expected results of using muscles in a
strenuous fashion; however, many changes take place at the cellular level, which in turn
have the potential to produce a cascade of events that move beyond those rudimentary
actions necessary to life (Nagelhout, 2014).
Potential Adverse Effects of Sustained Muscle Contraction
When a cell depolarizes, one of the electrolyte exchanges that occurs is between
sodium and potassium. As mentioned previously, sodium (the primary extracellular
positively charged ion) enters the cell when it is depolarized. At the same time,
potassium, the primary intracellular positively charged electrolyte, leaves the cell.
During sustained depolarization, since potassium is unable to reenter the cell, it is
introduced into the plasma. Potassium is regulated within tight margins in serum plasma
by the kidneys (3.5 – 5.0 mmol/L); too little or too much can have devastating effects on
cardiac function, including death (Nagelhout, 2014). The sustained contractions by
succinylcholine can increase plasma potassium up to 0.5 mmol/L (Hager, 2019).
Nagelhout (2014) suggests possible increases of up to 1.0 mmol/L. High plasma
potassium levels over 5.5 mmol/L is considered hyperkalemia, while levels higher than
6.0 mmol/L can produce serious cardiac events and may require immediate treatment. A
modest increase is usually insignificant in terms of clinical practice; however, if a patient
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has high potassium levels at baseline (e.g. due to kidney disease), this becomes especially
dangerous. Other patient populations that are susceptible to adverse effects of
hyperkalemia are burn and trauma victims and therefore succinylcholine is
contraindicated in these patients (Hager, 2019).
Continued muscular contraction increases the tissue’s oxygen requirements,
which in turn increases the body’s basal metabolic rate. This increased metabolism is the
mechanism by which energy is changed into the form of heat. The sustained contraction
of muscles uses more oxygen than is supplied. Muscle tissue then changes from aerobic
to anaerobic metabolism, which produces lactic acid, which is converted to lactate and
hydrogen ions. It is the lactate that builds up in the muscle tissue that causes pain in
subsequent days. Elevated temperature (hyperthermia) and muscle pain (myalgia) are
also potential adverse effects of succinylcholine-induced fasciculations (Gulenay &
Mathai, 2018).
Pain. Pain is an incredibly complex concept that involves various categories and
descriptions. For example, it may be classified in terms of longevity (chronic vs. acute)
and/or the underlying source (nociceptive vs. non-nociceptive). Nociceptive pain
involves the stimulation of specific nerve endings in specific locations of the body that
produce a pain response. Alternately, non-nociceptive pain involves damage to structures
of the central or peripheral nervous systems. This type of pain often has no identifiable
cause. Additionally, it is multidimensional in the way it is experienced, involving
sensory and emotional components (Nagelhout, 2014).
Several neurotransmitters (NT) and chemicals in the body serve to enhance or
suppress pain signals. These include Substance P, bradykinin, prostaglandins, serotonin,
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and glutamate among several others. As some form of tissue damage occurs, these
chemicals and NT stimulate nociceptors and a pain impulse is generated. This impulse is
then transmitted from the peripheral nervous system (PNS) to the central nervous system
(CNS), which includes the spinal cord and brain. By a complex communication system,
these pain signals ascend the spinal cord and are finally perceived as pain in various
locations in the brain. The brain then sends signals back through the spinal cord to be
transmitted to the periphery. At that point, motor, chemical, and/or physiologic responses
occur. For example, a motor response includes the removal of a hand from a painful
stimulus (like a hot stove). A chemical response includes the release of chemicals that
influences further pain perceptions. Finally, physiologic responses include a faster heart
rate, faster respiration rate, swelling at the site of injury, and other reactions (Nagelhout,
2014).
Pain, including postoperative pain and myalgia (muscle pain) affects various
populations differently. Regarding postoperative pain, there is a lower incidence in
males, those who take part in muscular exercise or activity, and patients at both extremes
of age (the very old and the very young). Pain also occurs with increased severity in
patients who ambulate earlier in the postoperative period. Additionally, there is a
constellation of factors that may either mask or exaggerate pain in general, such as
biologic, cultural, emotional, and social considerations (Nagelhout, 2014).
The issue of pain becomes clinically significant because of the relationship
between patient perceptions of pain, associated stress, and delayed healing time. Healing
is a complex continuum with several stages including inflammation, tissue remodeling,
and hemostasis. At the proper time, in the proper sequence, and for the proper duration

10

of time, these stages must occur for healing to occur. Pain is one of many factors that can
influence wound healing by interfering with this process (Guo & DiPietro, 2010).
Therefore, the reduction of stimuli that causes pain, including myalgias, should be a
significant focus in the clinical setting.
Myalgia. The sustained contraction of muscle fibers during succinylcholine
administration often produces postoperative myalgia, which may be delayed up to the
fourth postoperative day. However, the presence or absence of fasciculations is not
predictive of subsequent myalgia. Some patients may experience fasciculations but have
no postoperative myalgia, while others may have no visible fasciculations yet suffer from
postoperative myalgia (Abbas et al., 2009). Similar to general pain, myalgia tends to
affect populations differently. Some factors include patient age, surgical position, and
type of surgery. Additionally, males tend to have fewer complaints of myalgia than
females (Hochhalter, 1996). It is unknown if these factors may or may not have any
connection to the use of succinylcholine. Therefore, one cannot definitively conclude
that postoperative myalgia is a consequence of succinylcholine administration as opposed
to one or more of these other factors.
Myalgia occurs due to the activation of nociceptors, which are receptors that are
specialized to respond to tissue-damaging stimuli. The tissue damage is then perceived
subjectively as pain. Stimuli are generally either mechanical or chemical in origin.
Tissue trauma is an example of mechanical stimuli, while adenosine triphosphate (ATP),
protons (H+ ion), and substance P (SP) are examples of chemical stimuli. Additionally,
pathophysiological alterations of tissue are accompanied by a decrease in potential
hydrogen (pH), making the tissue acidic. An acidic pH level in muscle tissue is a major
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factor that leads to muscular pain (Mense, 2008). In this context, chemical activation is
the factor to be considered. Specifically, muscular exercise in the absence of oxygen
produces lactate as a byproduct. Lactate has been implicated as a contributing factor in
pain because it acts on muscular innervation of sensory neurons (Ishii & Nishida, 2014).
Free radicals. An additional byproduct of muscle contractions (and subsequent
metabolism and cellular function) are free radicals (FR), which can be both beneficial and
toxic to the body. The body produces endogenous antioxidants, but at times the
production of FR exceeds the capabilities of the body’s natural FR “scavengers.” When
FR accumulate in the body, a process called oxidative damage occurs. This refers to
damage done to a wide array of biomolecules in an indiscriminate and arbitrary manner,
which then contributes to pain. Simioni et al. (2017) demonstrated that a relationship
exists between pain and oxidative stress. Murphy, Myers, Davies, Webster, and Jones
(1992) note that FR in some way contribute to tissue injury, resulting in many acute
conditions. Free radicals have been suggested as causing postoperative myalgia.
Recently, antioxidants have been investigated as having a potential pain-relieving
mechanism. Propofol is one such FR scavenger, and both single-dose and continuous
intravenous infusions have been effective in preventing postoperative myalgia connected
with succinylcholine administration (Kararmaz, Kaya, Turhanoglu, & Ozyilmaz, 2003).
Since pain is a complex concept with varying pathways in the body, it makes sense that a
diversity of agents (not simply non-depolarizing muscle relaxants), are being used in the
prevention of myalgias associated with succinylcholine.
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Measuring Fasciculations and Pain
Measuring Fasciculations. Visible signs and symptoms of many disease
processes can be subjective, and muscle fasciculations are no different. In a study done
by Abbas et al. (2009), fasciculations were measured using a four-point scale from a prior
study from 1987. The authors used a four-point numeric tool that scored fasciculations
from 00 (no fasciculations) to 03 (severe fasciculations). Mild fasciculations were scored
as 01, while 02 indicated moderate fasciculations. However, even though the difference
between the absence and presence of fasciculations is essentially binary, the difference
between large muscle twitches and major limb movements may be subjective depending
on the clinician. One may interpret major muscle movement as limb movement, in part
because limbs often contain major muscle groups. Additionally, if a patient were in a
supine position, an anesthesia provider could not visibly observe fasciculations of back
muscles. A study by Khan, Siddiqi, Anjum, and Hamza (2017) used a similar four-tiered
0-3 scale. Virtually every study that measures fasciculations uses a four-tiered system as
described above; the major differences are the specific descriptions of the tiers.
Measuring Pain. At baseline, pain scores are subjective in nature. Pain
perception varies in patients with functional abilities or disabilities. Other factors such as
personal motivation, social supports, cultural, and psychological factors also have an
effect on pain perception. The continuum of healthcare has brought us to the current use
of a 0-10 pain scale. While this can be very helpful, it has drawbacks due to the
subjective nature of pain and varying levels of sensitivity and tolerance (Krebs, Carey, &
Weinberger, 2007). Abbas et al. (2009) cite a 1962 study which measures pain as it
relates to functional disability. This measurement tool was also a four-point numeric
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scale ranging from 00 to 03; 00 indicated no pain, while 03 indicated pain that involved
more than one site and included functional disability. Khan et al. (2017) also used a 0 –3
pain scale. The authors not only described levels 1 –3 as mild, moderate, and severe,
they also included the relative necessity of treatment (e.g. level 1 required no treatment,
level 2 required treatment, and level 3 required additional treatment).
Pretreatment Modalities
Over the decades, clinicians have been experimenting with a variety of ways to
attenuate succinylcholine-induced fasciculations. This includes drugs from several drug
classes, which work by various mechanisms of action, and include opioids, antiepileptics, non-steroidal anti-inflammatory agents, gamma aminobutyric acid (GABA)
agonists, and others (Khan et al., 2017).
Non-depolarizing muscle relaxants. Because of the mechanism of action of this
drug class described above, there are fewer receptors available for succinylcholine to
occupy. This produces action potentials that are not as intense or sustained as they would
otherwise be if succinylcholine had full access to all receptors. For this reason, this drug
class has been highly popular as regards a pretreatment strategy. It has also been
frequently studied and shown to be efficacious for this purpose.
GABA agonists. Propofol, gabapentin, and pregabalin are drugs that act on the
receptor that deals with the neurotransmitter GABA, which is the body’s main inhibitory
neurotransmitter. As an inhibitory neurotransmitter, it blocks particular brain signals,
which tends to decrease activity in the nervous system. Since fasciculations are a
function of the nervous system, inhibiting these signals has been found to block
fasciculations to some degree. Gabapentin and pregabalin in particular potentiate GABA
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as well as inhibit the release of calcium ions inside neurons and muscle cells (Khan et al.,
2017).
Magnesium sulphate. Magnesium sulphate’s exact functions are controversial,
but it has been shown to minimize two undesirable facets of intubation. First, as an
adrenergic antagonist, it blocks catecholamine release during laryngoscopy, including
raised heart rate and blood pressure. Second, it has been shown to decrease
fasciculations. The authors of one study state that it controls the increase of potassium
concentration, thereby attenuating muscular action potentials (Ahsan et al., 2016).
However, Sakuraba et al. (2006) state that while it does decrease fasciculations, it has no
effect on potassium concentration. Therefore, while it has efficacy in reducing
fasciculations, its exact mechanism remains under debate.
Opioids. Opioids, especially remifentanil, have been used in both the induction
and maintenance phases of anesthesia for decades. Like magnesium sulphate, they blunt
the sympathetic response to laryngoscopy. They also have been shown to reduce the
intensity of succinylcholine-induced fasciculations, although the mechanism by which
this occurs remains unexplained (Yun et al., 2010).
Next, the theoretical framework will be discussed.
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Theoretical Framework
Random controlled trials (RTCs) are individual snapshots of the overall portrait of
a particular topic. Each trial, regardless of sample size, contributes information to the
larger body of literature. Dozens or hundreds of trials are conducted in various
institutions, cities, and countries around the world. An analysis of related studies that
compare results is able to greatly enhance the generalizability of the findings, thus
making an application in the clinical setting more likely. The collection and distillation
of random controlled trials is a necessary step in the research process. Systematic
reviews and meta-analyses are tools that enable researchers to synthesize data and
attempt to interpret findings in a way that furthers the scope and enhances the knowledge
base of a particular area of research. Additionally, systematic reviews may assist in
assessing the quality of studies in terms of methods and processes (Liberati et al., 2009).
Systematic reviews are facilitated by frameworks such as the Preferred Reporting
Items for Systematic review and Meta-Analyses (PRISMA). Using this framework
enables one to compile and examine the strengths and weaknesses of each RCT, thus
revealing a wide-angle viewpoint instead of a close-up, focused glimpse of a topic.
PRISMA is an accepted protocol for systematic reviews largely because the flow and
results depend heavily on both the scope and quality of the studies included. Therefore,
the PRISMA Statement (Figure 1) was developed to guide the authors of systematic
reviews. The Statement is a checklist consisting of twenty-seven items as well as a
flowchart (Figure 2) to follow step by step. In using these, PRISMA helps to govern the
analysis of RCTs, thus maintaining consistency among systematic reviews and metaanalyses (Liberati et al., 2009).
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Reported
Section/topic

#

Checklist item

on page
#

TITLE
Title

1

Identify the report as a systematic review, meta-analysis, or both.

1

2

Provide a structured summary including, as applicable: background; objectives; data
sources; study eligibility criteria, participants, and interventions; study appraisal and
synthesis methods; results; limitations; conclusions and implications of key findings;
systematic review registration number.

3

Rationale

3

Describe the rationale for the review in the context of what is already known.

5

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants,
interventions, comparisons, outcomes, and study design (PICOS).

6

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address),
and, if available, provide registration information including registration number.

19-22

ABSTRACT
Structured summary

INTRODUCTION

METHODS
Protocol and
registration

17

Eligibility criteria

Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics
(e.g., years considered, language, publication status) used as criteria for eligibility, giving
rationale.
7 Describe all information sources (e.g., databases with dates of coverage, contact with study
authors to identify additional studies) in the search and date last searched.
8 Present full electronic search strategy for at least one database, including any limits used,
such that it could be repeated.
9 State the process for selecting studies (i.e., screening, eligibility, included in systematic
review, and, if applicable, included in the meta-analysis).
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in
duplicate) and any processes for obtaining and confirming data from investigators.

23

24

individual studies

11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and
any assumptions and simplifications made.
12 Describe methods used for assessing risk of bias of individual studies (including
specification of whether this was done at the study or outcome level), and how this
information is to be used in any data synthesis.

Summary measures

13 State the principal summary measures (e.g., risk ratio, difference in means).

n/a

Synthesis of results

14 Describe the methods of handling data and combining results of studies, if done, including
measures of consistency (e.g., I2) for each meta-analysis.

24

Information sources
Search
Study selection
Data collection
process
Data items
Risk of bias in

6

23
23-24
24
24-25

37

18

Reported
Section/topic

#

Checklist item
on page #

Risk of bias across
studies
Additional analyses

15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g.,
publication bias, selective reporting within studies).
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, metaregression), if done, indicating which were pre-specified.

37

17 Give numbers of studies screened, assessed for eligibility, and included in the review, with
reasons for exclusions at each stage, ideally with a flow diagram.
18 For each study, present characteristics for which data were extracted (e.g., study size,
PICOS, follow-up period) and provide the citations.
19 Present data on risk of bias of each study and, if available, any outcome level assessment
(see item 12).

24

20 For all outcomes considered (benefits or harms), present, for each study: (a) simple
summary data for each intervention group (b) effect estimates and confidence intervals,
ideally with a forest plot.

33-34

21 Present results of each meta-analysis done, including confidence intervals and measures of
consistency.
22 Present results of any assessment of risk of bias across studies (see Item 15).

34

23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, metaregression [see Item 16]).

34

27

RESULTS
Study selection
Study characteristics
Risk of bias within
studies
Results of individual
studies
Synthesis of results
Risk of bias across
studies
Additional analysis

28-34
37

37

19

DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome;
consider their relevance to key groups (e.g., healthcare providers, users, and policy
makers).
Limitations
25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g.,
incomplete retrieval of identified research, reporting bias).
Conclusions
26 Provide a general interpretation of the results in the context of other evidence, and
implications for future research.
FUNDING

34-36

Funding

n/a

27 Describe sources of funding for the systematic review and other support (e.g., supply of
data); role of funders for the systematic review.

Figure 1. Completed PRISMA checklist

36-37
38
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Records identified through
database searching (n = 20)

20

Additional records identified
through other sources (n = 0)

Records after duplicates removed
(n = 16)

Records screened
(n = 16)

Full-text articles
assessed for eligibility
(n = 16)

Studies included in qualitative
synthesis (n = 4)

Studies included in
quantitative synthesis (metaanalysis) (n = 4)

Figure 2. Completed PRISMA flowchart
Next the methods will be discussed.

Records excluded
(n = 0)
Full-text articles
excluded (n=12), with
reasons:
Not in English (n=1)
Not an RCT (n=3)
Pediatric population
(n=1)
Pretreatment agent not
assessed (n=2)
Post-op myalgia not
assessed (n=3)
Fasciculations not focus
of study (n=2)

21

Methods
Purpose
The purpose of this project was to conduct a systematic review to compare
pretreatment modalities for the prevention of succinylcholine-induced fasciculations in
adults undergoing endotracheal intubation. The research question that will be examined
is: Of the known and available pretreatment modalities for the prevention of
succinylcholine-induced fasciculations, which modality has the greatest efficacy as
measured by postoperative myalgia?
Inclusion and exclusion criteria
Inclusion criteria were: (1) randomized controlled trials from 2010 to 2020, (2) in
adult patients aged 18 and older, (3) with a primary focus on succinylcholine-induced
fasciculations, (4) American Society of Anesthesiologists (ASA) classes I and II, (5) and
written in English. Pediatric studies were excluded due to significant physiological
differences in organ maturation, drug metabolism, medication dosing, and drug response
(Nagelhout, 2014). The ASA classifies patients according to physical status with regards
to the presence & severity of systemic disease (e.g. hypertension, diabetes, heart failure),
using class I through V. Class III and above indicate patients with severe systemic
disturbances that either limit activity or are life-threatening, or those for whom surgery is
a resuscitative effort, with a minimal chance of survival (Nagelhout, 2014). Therefore,
class III and above were excluded due to these confounding factors.
Search strategy
PubMed and Web of Science were searched for randomized controlled trials using
the following search criteria: (1) randomized clinical trials, (2) “succinylcholine” in title
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or abstract, (3) “fasciculation*” in title or abstract, and (4) date range 2010 to 2020.
Fasciculation was searched using the wildcard “*” to capture both “fasciculation” and
“fasciculations.” The PubMed search initially yielded eleven studies (n=11) and the Web
of Science search yielded nine (n=9), for a total of twenty studies. Four were rejected as
duplicates, two were rejected because the study was not examining a pretreatment agent,
two were rejected because fasciculations were not the focus of the study, one was
rejected because English was not the primary language, one was rejected because
pediatric patients were included, three were rejected because the studies did not assess
postoperative myalgia, and three were rejected because the studies were not randomized
controlled trials. This yielded a total of four studies that were included in this systematic
review.
Data collection and synthesis approach
The results of each RCT were placed in two tables. Table 1 displays data that was
collected from each RCT and includes the author, sample size, dose of succinylcholine,
pretreatment agent, and the percentage of patients with fasciculations at each level of a 4point scale. Table 2 will display data that reflects the author, pretreatment agent utilized,
the time-frame myalgia was measured in (hours postoperative), as well as incidence and
severity of myalgia (using a similar 4-point scale).
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Sample Table 1
Author

Sample
size
(n)

Dose
Succinylcholine
(mg/kg)

Pretreatment
agent

Patients with
fasciculations
(intervention
group)
0=
1=
2=
3=

Patients with
fasciculations
(control group)
0=
1=
2=
3=

Sample Table 2
Author

Dose
Succinylcholine
(mg/kg)

Pretreatment
agent

Myalgia at 24
hrs
postoperative
(intervention
group)
0=
1=
2=
3=

Myalgia at 24
hrs
postoperative
(control group)
0=
1=
2=
3=

Critical appraisal instruments
The Critical Appraisal Skills Programme (CASP) will be used to critically
appraise each RCT (Figure 3). The Critical Appraisal Skills Programme contains eleven
questions that are applied to each study. The answers to these questions are analyzed to
determine the validity, relevance, trustworthiness, and usefulness of studies. Within the
first two questions, it can be determined if that particular study is valid enough to
continue the appraisal (Critical Appraisal Skills Programme [CASP], 2017). By critically
appraising each RCT, conclusions and results are anticipated to be sufficient to make
informed conclusions and recommend further research in this area.
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Figure 3. Critical Appraisal Skills Programme (CASP) randomized control trials
checklist
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Cross Analysis
After critically appraising each randomized control trial utilizing CASP, the
studies will be evaluated to compare similarities and differences across the studies.
Fasciculations and postoperative myalgia will be assessed according to a 24-hour
timeframe, which all studies reviewed used. These will be divided into two columns:
none to mild with a score of 0 or 1, or moderate to severe with a score of 2 or 3 (table 3).
Sample Table 3 – Cross Analysis Tool
Author

Pretreatment
Agent

Fasciculation Fasciculation
score of 0 or 1 score of 2 or
3

Myalgia score Myalgia score
of 0-1 at 24
of 2-3 at 24
hrs
hrs

Dissemination of Findings
Ideally, findings of a systematic review should influence clinical practice if the
findings are significant. With this in view, the optimal audience would be anesthesia
providers. At present, a major paper and poster presentation will be used for initial
dissemination.
Next, the results of this systematic review will be presented.
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Results
The completed PRISMA flow diagram in the theoretical framework section
(Figure 2) demonstrates the process used which yielded the final four studies that were
reviewed, as described in the search strategy of the methods section. The results from
each of these studies were placed in Tables 1 and 2. Cross analysis was performed and
the results were placed in Table 3. All of these appear at the end of the results section.
Additionally, a CASP table was completed for each study (Appendix A).
Yun et al. (2010) evaluated the use of remifentanil as a pretreatment modality. In
this double-blind study, two equal groups (n=20) of adult patients were analyzed under
controlled intubating conditions. One group received remifentanil while the other
received normal saline. Both subjective and objective means were utilized to determine
presence and severity of fasciculations. The intensity and duration of fasciculations were
noted and recorded following administration of succinylcholine. 90% of the control
group experienced fasciculations while 85% of the intervention group experienced
fasciculations. Further, the duration of fasciculations in the intervention group was 41.6
seconds vs. 59.6 seconds in the control group. Myalgia was recorded twenty-four hours
after the time of induction. Objective data included the use of electromyography
whereby muscle action potentials are measured using electrodes. Recordings of the
amplitude of the action potentials are able to quantify the degree of fasciculations.
Additionally, serum potassium levels were analyzed five minutes after succinylcholine
administration and creatine kinase (CK) levels were analyzed twenty-four hours after
induction time. Both potassium and CK give an indication of muscle activity and cellular
breakdown. The results showed a decrease in the intensity of fasciculations in the
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remifentanil group, but similarities were found in both incidence and duration of
fasciculations between the groups. With respect to myalgia, there was no statistically
significant difference between the two groups: only one patient experienced mild
myalgia in the remifentanil group, and only two experienced mild myalgia in the control
group. Moderate and severe myalgia were absent in both groups. The authors concluded
that remifentanil was able to attenuate the intensity of fasciculations but produced no
notable effect on postoperative myalgia. The authors suggested that dosing regimens
could be studied and potentially optimized for this use.
Khan, Siddiqi, Anjum, & Hamza (2017) performed a randomized controlled study
using pregabalin, an anti-epileptic drug that acts on the neurotransmitter GABA. Seventy
patients were divided into two equal groups. The control group received a placebo pill
while the intervention group were administered 150 mg of pregabalin, both two hours
before induction of anesthesia and administration of succinylcholine. Fasciculation
incidence and intensity was measured using a four-point scale by a blinded resident
doctor. Additionally, 24 hours after the surgery, myalgia was assessed using a similar
four-point scale. The results demonstrated a significant difference between the incidence
and severity of myalgia in the first 24 hours of the postoperative period (p=0.000).
However, the incidence of fasciculations was not statistically significant between the two
groups (p=0.096), although the severity seemed to be decreased in the intervention group.
Further, all patients who received pregabalin tolerated it well, and none experienced any
significant side effects of the drug (e.g. somnolence). Limitations of this study include
the fact that it was a single type of surgical procedure (laparoscopic cholecystectomy) at a
single site. However, a wider scope of surgical procedures will most likely not influence
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generalizability to any significant degree since the only issue being assessed is
fasciculations associated with the induction/intubation period. Since postoperative
myalgia is being assessed, one issue may be that other procedures have a higher degree of
postoperative pain associated with them. This may influence a patient’s assessment of
myalgia that is strictly due to fasciculations.
Pandey, Tripathi, Joshi, Karna, Singh, and Singh (2012) studied gabapentin,
another anti-epileptic drug similar to pregabalin. Seventy patients participated in this
study. The intervention group (n=35) received an oral dose (600 mg) of gabapentin two
hours prior to surgery while the control group (n=35) received a placebo (also
administered orally). 1.5 mg/kg of succinylcholine was used in both groups, and all other
adjunct medications (fentanyl, thiopentone, and maintenance drugs) were the same. The
results showed a significant decrease in the postoperative incidence and severity of
myalgia (p<0.05) between the groups. In the control group, twenty experienced myalgia
in the first 24 hours postoperative. This was contrasted with only eleven in the
intervention group experiencing myalgia in the same time period. There was no
statistically significant difference on the incidence or severity of fasciculations between
the groups. However, since myalgia involves the patient’s perception of pain and/or
discomfort, it is a more significant measure of the efficacy of a pretreatment drug as
compared to the measure of the incidence and/or severity of fasciculations, which the
patient is unaware of. An additional discovery in this study was that the use of
gabapentin decreased the need for intra-operative pain medications, measured by the
administration of fentanyl. As with Khan et al., this study assessed only laparoscopic
cholecystectomy procedures at a single site.
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Vyankatesh, Kiran, and Satish (2016) performed a study that compared two nondepolarizing muscle relaxant drugs against both one another as well as a control group.
One hundred fifty patients were divided into three equal groups of fifty. Group NS
(control group) received 2 mL of normal saline, group V received 0.1 mg/kg of
vecuronium, and group R received 0.06 mg/kg of rocuronium for pretreatment. ASA I &
II patients of both genders with a mean age between 35.5 and 37.3 were included in this
study. The results showed that the group that received rocuronium had the largest
number of patients with fasciculations graded as 0 or 1 (100%), followed by the group
that received vecuronium (88%). The control group had just 28% with a 0 or 1 grade.
The inverse was true regarding fasciculations with a grade of 2 or 3: the control group
(group NS) had 72% at that severity level, group V had 24%, while group R had 0%.
Concerning postoperative myalgia at 24 hours out, the results essentially followed those
regarding fasciculations, as displayed in table 3. Group R had the highest percentage in
the 0 category, followed by group V and then by group NS. As for scores 1, 2, and 3
(mild, moderate, and severe, respectively) on the four-point myalgia scale, group NS had
the most of all three groups at each level, followed by group V, with group R showing the
least percentage of postoperative myalgia of all groups. Of note, this was the only study
in this review that assessed myalgia at a postoperative timeframe of greater than 24
hours. The results basically mirrored those of postoperative day 1. However (and
interestingly), the percentages of all three groups at level 0 (no myalgia) decreased, while
those of the other levels of myalgia increased with only a few exceptions: at no
assessment was there level 3 myalgia in group V, and at no assessment were there levels
2 or 3 in group R.
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One error was noted in the fasciculation-scoring table of this study for the group
that received vecuronium: the amount of participants added up to 56 instead of 50;
therefore, the percentages also ended up high (112%). This was the only table noted to
have this error; all others correctly added up to a total of 50 in the group. These incorrect
results are still included in this systematic review as they appear in the study; however,
the reader should be aware that the results are not completely accurate as regards
fasciculations. Since the myalgia scores are the main end focus of this review, the study
in its entirety was not excluded since the data from the myalgia table added up correctly.
This study when compared to the other three displayed more tables showing a
greater breadth of clinically relevant outcomes. These included urine myoglobin, serum
CPK levels, and serum potassium levels, all of which are relevant sequelae of
succinylcholine administration.
Table 1 – Data Collection Tool 1 – RESULTS
Author

Sample
size
(n)

Dose
Succinylcholine
(mg/kg)

Pretreatment
agent

Yun et al.,
2010

n=40

1

Remifentanil

Khan et al.,
2017

n=70

1.5

Pregabalin

Pandey,
Tripathi,
Joshi, Karna,
Singh, &
Singh, 2012

n=70

1.5

Gabapentin

Patients with
fasciculations
(intervention
group)
0 = 15%
1 = 65%
2 = 20%
3 = 0%
0 = 8.5%
1 = 48.5%
2 = 40 %
3 = 3%
0 = 14%
1 = 46%
2 = 34%
3 = 6%

Patients with
fasciculations
(control
group)
0 = 10%
1 = 5%
2 = 60%
3 = 25%
0 = 8.5%
1 = 28.5%
2 = 43%
3 = 20%
0 = 17%
1 = 23%
2 = 49%
3 = 11%
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Vyankatesh,
Kiran, &
Satish, 2016

n=150

1.5

Rocuronium
(vs.)

Vecuronium*

0 = 76%
1 = 24%
2 = 0%
3 = 0%
0 = 52%
1 = 36%
2 = 12%
3 = 12%

* results add
up to 112% as
noted
Table 2 – Data Collection Tool 2 – RESULTS
Author

Pretreatment
agent

Yun et al.,
2010

Remifentanil

Khan et al.,
2017

Pregabalin

Pandey et
al., 2012

Gabapentin

Vyankatesh,
Kiran, &
Satish, 2016

Rocuronium

Vecuronium

Myalgia at 24
hrs postoperative
(intervention
group)
0 = 95%
1 = 5%
2 = 0%
3 = 0%
0 = 31.4%
1 = 54.3%
2 = 14.3%
3 = 0%
0 = 57%
1 = 31.5%
2 = 11.5%
3 = 0%
0 = 88%
1 = 12%
2 = 0%
3 = 0%
0 = 72%
1 = 20%
2 = 8%
3 = 0%

Myalgia at 24
hrs postoperative
(control group)
0 = 90%
1= 10%
2 = 0%
3 = 0%
0 = 6%
1= 29%
2 = 51%
3 = 14%
0 = 31%
1= 40%
2 = 29%
3 = 0%
0 = 16%
1= 52%
2 = 24%
3 = 8%

0 = 0%
1 = 28%
2 = 60%
3 = 12%
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Table 3 – Cross Analysis Tool - RESULTS
Author

Yun et al.,
2010
Khan et al.,
2017
Pandey et
al., 2012
Vyankatesh,
Kiran, &
Satish, 2016

Pretreatment
Agent
(pretreatment
modality)
Remifentanil

Fasciculation Fasciculation
score of 0 or score of 2 or
1
3

Myalgia
score of 0-1
at 24 hrs

Myalgia
score of 2-3
at 24 hrs

80%

20%

100%

0%

Pregabalin

57%

43%

85.7%

7.1%

Gabapentin

60%

40%

88.5%

11.5%

Rocuronium
vs.
Vecuronium*

100%

0%

100%

0%

88%

24%

92%

8%

* fasciculation
results add up
to 112% as
noted
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Summary and Conclusions
Succinylcholine is a popular muscle relaxant useful in a number of tracheal
intubation situations, particularly rapid sequence intubation (RSI). Its rapid onset and
metabolism by innate enzymes make it an ideal choice for this purpose, especially when
coupled with shorter procedures which do not require longer lengths of time of muscle
relaxation. However, its side effect profile includes fasciculations, which quite often
produce myalgias in the immediate postoperative period (Yun et al., 2010). Because of
this, clinicians have experimented with a variety of other agents to use as a pretreatment
adjunct to succinylcholine in an attempt to attenuate or eliminate fasciculations and
myalgias. Many of these other agents, because of their mechanisms of action, have been
shown to be beneficial for this purpose, with varying degrees of success.
The purpose of this systematic review was to identify agents that reduce or
eliminate fasciculations as evidenced by an absence of postoperative myalgias, compare
them using a variety of tools, and attempt to identify a single agent that is superior to the
others. The literature review focused on cell receptor theory, the mechanism of muscle
contraction, the mechanism of action of muscle relaxant drugs used in anesthesia, and
pain. The theoretical framework utilized both PRISMA and CASP, which are considered
the gold standard for systematic reviews. The former includes a checklist and flowchart
with which to organize, include, or exclude studies depending on their applicability,
while with the latter one is able to judge the integrity, validity, and rigor of a study or
experiment. Using these in tandem, one may form certain conclusions and identify
correlations that may be useful in answering the research question. This analysis was
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performed on the four studies that met criteria for inclusion. Cross analysis was then
performed on the data that was collected, which establishes certain findings.
To summarize, the results of the cross analysis (Table 3) demonstrate that every
agent used to reduce fasciculations was efficacious, to varying degrees. To be clear, even
though both rocuronium and remifentanil had myalgia scores of 100% in the 0 or 1 score
levels and 0% in the 2 or 3 score levels, there is a vast difference between the two. The
difference between the rocuronium and control groups was significant, even though a p
value was not specifically given. In the remifentanil study, this percentage reflected only
one patient who experienced myalgia, while there were only two in the control group;
therefore, this is not statistically significant. However, it is interesting to note that in the
remifentanil study (Yun et al., 2010), a total of only 3 participants reported myalgia of
any severity, which is not even 1% of the whole. That is a significantly lower percentage
than any of the other studies. Perhaps there is a correlation between the dose of
succinylcholine as compared to the other studies; in this study, only 1 mg/kg was used,
while the other three studies used 1.5 mg/kg. Possibly a reduced dose of succinylcholine
would produce acceptable intubating conditions while at the same time mitigating its own
postoperative myalgia. Yun et al. did not note any difficult intubating conditions as a
result of the lower dose of succinylcholine. Additionally, this was the only study that
noted the duration in seconds of the fasciculations. It would be interesting in future
research to compare incidence, severity, and duration of fasciculations as those factors
relate to postoperative myalgia.
This synthesis and evaluation points to the findings of this systematic review.
The research question asked which agent was the most efficacious in eliminating or
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reducing succinylcholine-induced fasciculations as measured by postoperative myalgia.
To this end, it seems that rocuronium, a nondepolarizing muscle relaxant, has the greatest
efficacy in the elimination and/or reduction of both the frequency and severity of both
fasciculations and myalgia as compared to a control group. However, as noted above, a
secondary finding seems to suggest that a lower dose of succinylcholine (with or without
a pretreatment agent,) may be used for intubation, and reduce fasciculations. This dosing
adjustment may in turn diminish postoperative myalgia.
There were a number of limitations identified while performing this systematic
review. Only the most recent studies were included (2010-present). While this focuses
on current modalities and clinical practice, it excludes other agents that perhaps have not
been studied recently but that are still in use clinically, or agents that are used elsewhere
globally that are more accessible and less expensive than their first-world counterparts.
In every study, only patients classified as ASA I or II were included, which could limit
generalizability. Additionally, only certain procedures were reflected in these studies.
Two of these were laparoscopic cholecystectomy, one (Yun et al., 2010) included only
elective otolaryngological surgery specifically because it carries a minimal risk of serum
CK increases, and the last did not disclose the type(s) of procedure(s). RSI is used in
many emergent, trauma, and difficult airway cases; it is difficult to know if there are
confounding factors associated with these types of procedures that do not exist in a
relatively controlled environment. Additionally, patients with known conditions such as
neuromuscular diseases or morbid obesity, and those at the extremes of age were
excluded (Yun et al., 2010). Some of these conditions contraindicate the use of
succinylcholine (e.g. certain neuromuscular diseases), but others do not; however,
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without studying a wider population, including special populations, results may not be
generalizable.
Risk of bias is always present in any study; however it can be minimized by being
transparent as regards the methods and reporting of the results. These four studies were
blinded, randomized controlled trials, with methods clearly communicated and therefore
easily duplicated. Therefore, the risk of bias seems quite negligible. However, the
subjectivity as regards the reporting of both fasciculations and postoperative myalgia
could contain varying degrees of risk of bias. Since pain contains physical, emotional,
and psychological elements, the reporting of postoperative pain may be laden with bias:
some patients may feel free to report (with or without exaggeration), while others may be
relatively stoic in their approach to pain and reporting it.
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Recommendations and Implications for Advanced Nursing Practice
The ultimate goal for research is to impact clinical practice. It is obvious that
fasciculations associated with the administration of succinylcholine very often produce
myalgia for the patient in the postoperative period; this has been a clinical concern for
decades. This impacts the patient’s perception of the healthcare system in general, which
flows down to individual disciplines within the healthcare system, including anesthesia.
Therefore, minimizing or eliminating this unpleasant side effect has been, and should
continue to be, a focus for APN anesthesia providers. Various drugs that can be used for
this purpose are readily available and should be used if there are no contraindications.
This would serve to increase the quality of our practice, and in a broad sense be a way
that we advocate for our patients’ postoperative comfort.
As noted above with the different dosing of succinylcholine, future research could
focus on using smaller doses of succinylcholine in conjunction with a pretreatment agent
in order to reduce or eliminate myalgia. Centrally located nerves and muscles (e.g. face,
throat) are affected before peripheral nerves and muscles (arms, hands, legs); therefore,
could an alternate dosing strategy be developed to produce enough paralysis for
intubation, without the need to affect 100% of every peripheral receptor?
Results shown here, as well as future research, can be promulgated on a broader
scale. This could include various publications and conference presentations. Ultimately,
it is up to each individual provider of anesthesia to be an active and critical consumer of
research information in whatever form it takes, and seek to implement new, clinically
relevant data into practice. Additionally, policy development for the APN is an important
facet of clinical practice. This does not always need to be at a national or state level; we
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have the ability to develop protocols and policies at individual institutions regarding more
comprehensive patient education before a procedure (i.e. possible symptoms they may
experience postoperatively) as well as patient follow-up in the postoperative period. This
may go a long way to build trust between patients and health care providers.
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Appendix A
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 1: Yun, M.J., Kim, Y.H., Go, Y.K., Shin, J.E., Ryu, C.G., Kim, W., Paik, N.J.,
Han, M.K., Do, S.H., & Jung, W.S. (2010). Remifentanil attenuates muscle fasciculations
by succinylcholine. Yonsei Medical Journal, 51(4).
A)

Are the results of the trial valid?
1. Did the trial address a clearly focused issue?

x

2. Was the assignment of patients to treatments randomized?

x

3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers, and study personnel “blind” to
treatment?
5. Were the groups similar at the start of the trial?

x

6. Aside from the experimental intervention, were the groups
treated equally?
B)
What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the treatment effect?

C)

Yes

Can’t
tell

No

x
x
x

40 otolaryngological
patients.
No statistically
significant decrease in
myalgia.

Will the results help locally?
9. Can the results be applied in your context? (or to the local
population)
10. Were all clinically important outcomes considered?

x

11. Are the benefits worth the harms and costs?

x

x
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 2: Khan, M.A., Siddiqi, K.J., Anjum, K.M., & Hamza, A. (2017). A randomized
controlled study on prevention of succinylcholine induced fasciculation and myalgia by
pretreatment with pregabalin in patients undergoing laparoscopic cholecystectomy.
Anaesthesia, Pain & Intensive Care, 21(4).
A)

Are the results of the trial valid?
1. Did the trial address a clearly focused issue?

x

2. Was the assignment of patients to treatments randomized?

x

3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers, and study personnel “blind” to
treatment?
5. Were the groups similar at the start of the trial?

x

6. Aside from the experimental intervention, were the groups
treated equally?
B)
What are the results?
7. How large was the treatment effect?

8. How precise was the estimate of the treatment effect?

C)

Yes

Can’t
tell

No

x
x
x

70 laparoscopic
cholecystectomy
patients.
Decrease of myalgia
was statistically
significant.

Will the results help locally?
9. Can the results be applied in your context? (or to the local
population)
10. Were all clinically important outcomes considered?

x

11. Are the benefits worth the harms and costs?

x

x
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 3: Pandey, C.K., Tripathi, M., Joshi, G., Karna, S.T., Singh, N., & Singh, P.K.
(2012). Prophylactic use of gabapentin for prevention of succinylcholine-induced
fasciculation and myalgia: a randomized, double-blinded, placebo-controlled study.
Journal of Postgraduate Medicine, 58(1). 19-22.
A)

Are the results of the trial valid?
1. Did the trial address a clearly focused issue?

x

2. Was the assignment of patients to treatments randomized?

x

3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers, and study personnel “blind” to
treatment?
5. Were the groups similar at the start of the trial?

x

6. Aside from the experimental intervention, were the groups
treated equally?
B)
What are the results?
7. How large was the treatment effect?

8. How precise was the estimate of the treatment effect?

C)

Yes

Can’t No
tell

x
x
x

70 laparoscopic
cholecystectomy
patients.
Decrease of myalgia
was statistically
significant.

Will the results help locally?
9. Can the results be applied in your context? (or to the local
population)
10. Were all clinically important outcomes considered?

x

11. Are the benefits worth the harms and costs?

x

x
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 4: Vyankatesh, J.S., Kiran, T.V., & Satish, D.G. (2016). Comparative study of
pretreatment with rocuronium and vecuronium in post succinylcholine fasciculation,
intubation condition and myalgia. Journal of Evolution of Medicine and Dental Sciences,
5:38), 2319-2324.
A)

Are the results of the trial valid?
1. Did the trial address a clearly focused issue?

x

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers, and study personnel
“blind” to treatment?
5. Were the groups similar at the start of the trial?

x

6. Aside from the experimental intervention, were the
groups treated equally?
B)
What are the results?

C)

Yes

Can’t
tell

No

x
x
x
x

7. How large was the treatment effect?

150 adult patients undergoing
elective surgery.

8. How precise was the estimate of the treatment effect?

Both Rocuronium and
Vecuronium were efficacious
and the decrease in myalgia was
statistically significant with
both drugs. However,
Rocuronium was noted to be
more efficacious as compared
to Vecuronium.

Will the results help locally?
9. Can the results be applied in your context? (or to the
local population)
10. Were all clinically important outcomes considered?

x

11. Are the benefits worth the harms and costs?

x

x
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